Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Costs and economics

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Before donanemab was approved, researchers built a computer model simulating lifetime outcomes for Alzheimer's patients to estimate whether aducanumab and donanemab were reasonably priced for the health benefit they provide. At the prices assumed in the model, both drugs cost far more per year of good-quality life gained than standard cost-effectiveness benchmarks, with aducanumab performing especially poorly and donanemab needing a much lower price to be considered good value.

What this study adds

Evidence grade: Moderate

Aducanumab performed especially poorly and donanemab needed a much lower price to be considered good value. Its stated limit: A modelling study based on simulated disease progression and extrapolated trial data rather than observed long-term outcomes; published before donanemab's actual FDA approval and pricing, so it used an assumed hypothetical price rather than the drug's real launch price.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ross, E. L., Weinberg, M. S., & Arnold, S. E. (2022). Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2022.0315

Vancouver

Ross EL, Weinberg MS, Arnold SE. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US. JAMA Neurology. 2022. doi:10.1001/jamaneurol.2022.0315. PMID: 35344024.

BibTeX

@article{ross2022-b0c356d3,
  author  = {Ross, E. L. and Weinberg, M. S. and Arnold, S. E.},
  title   = {{Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US}},
  journal = {JAMA Neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.0315},
  pmid    = {35344024},
  url     = {https://doi.org/10.1001/jamaneurol.2022.0315}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

Before donanemab was approved, researchers built a computer model simulating lifetime outcomes for Alzheimer's patients and found that at the prices assumed in the model, both aducanumab and donanemab cost far more per year of good-quality life gained than standard cost-effectiveness benchmarks. Aducanumab performed especially poorly and donanemab needed a much lower price to be considered good value.

Study details

Limitations

A modelling study based on simulated disease progression and extrapolated trial data rather than observed long-term outcomes; published before donanemab's actual FDA approval and pricing, so it used an assumed hypothetical price rather than the drug's real launch price.

How this study scored 52/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record left out, no data; Study design 3 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 2 of 2; Free to read left out, no data. 32 of the 62 points it could be judged on, which is 52 of 100. Total 52 of 100.32 of the 62 points we could judge = 52 of 100

Published in a leading specialty journal, and it is a computer model rather than new measurements. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 32 of the 62 points we could judge it on, which is 52 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA Neurology)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 3 / 12 A computer model rather than new measurements
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2022 — within 6 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 35344024)
Free to read — / 2 Access not recorded — left out of this score
Points 32 / 62 Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 32 of the 62 points we could judge it on is 52 out of 100.
Total 52 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.

Later studies that cite this one

14 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Costs and economics from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Costs and economics

See all studies in Costs and economics →